Skip to main content

Advertisement

Table 4 Literature review of patients harbouring compound EGFR mutations and PFS and response to first-generation TKIs between 2004 and 2017

From: First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Compound mutations Double common (n, mPFS, response) Common + rare (n, mPFS, response) Rare + rare (n, mPFS, response) Common + T790M (n, mPFS, response) Rare + T790M (n, mPFS, response)
Kobayashi et al. [8] None 3; 3 monthsa; 2 PR, 1 PD 4; 8 months; 4 PR None None
Zhang et al. [9] 3; 17.5 months; 1 CR, 1 PR, 1 NA None None None None
Hsieh et al. [10] None 1; 1.9 months; 1 SR 6; 11.6 months;
4 PR, 2 PD
None None
Hata et al. [11] 8; 12.7 months; 1 CR, 5 PR, 1 SD, 1 NA 8; 2.5 months; 2 PR, 1 SD, 2 PD, 3 NA None None None
Keam et al. [14] None 16; 8.1 months; 11 PR, 4 SD, 1 PD 3; 4.6 months; 1 PR, 1 PD, 1 NA 5; 8.0 months; 4 PR, 1 PD None
Xu et al. [16] 14; 9.53 months; 10 PR, 3 SD, 1 PD 18; 9.8 months; 10 PR, 5 SD, 3 PD None 9; 1.9 months; 2 PR, 3 SD, 4 PD None
Wu et al. [17] None 7; NA; 2 PR, 1 SD, 4 PD 3; NA; 2 PR, 1 PD None None
Chen et al. [18] None 10; 8.9 months; 4 PR, 6 NA None 3; 6.7 months; 1 PR, 1 SD, 1 NA 1; 6 months; SD
Wu et al. [21] None 12; 13.5 months; 10 PR, 1 SD, 1 PD 7; 4.2 months; 2 PR, 4 SD, 1 PD 2; NA; 2 PR None
Asahina et al. [26] None None 1; 1.1 months; PD None None
Zhang et al. [32] 2; 6.1 months; 2PR 7; NA; NA 11; NA; NA 8; 3.3 months; 1PR, 1SD, 6NA 3; NA; NA
Zhu et al. [33] None 3; 5.3 monthsa; 2SD, 1PD 5; 3.5 monthsa; 2 PR, 2 SD, 1 NA None None
Wu et al. [34] None 9; 8.6 months; 7 PR, 1 SD, 1 PD 4; 9.2 months; 2 PR, 1 PD, 1 SD None None
Yang et al. [35] 1; 2 months; 1 PD None None None None
Svaton et al. [36] None None 1; 8 months; 1 PR None None
Peng et al. [37] 2; 11.5 months; 1 PR, 1 SD 3; 10 months; 3 SD None 1; 10 months; 1 SD None
Baek et al. [38] 12; 7.4 months; 4 CR, 5 PR, 2 SD, 1 PD None 11; 5.1 months; 5 CR, 4 PR, 2 SD None None
Peng et al. [39] 2; 11.5 months; 1 PR, 1 SD 4; 8 months; 4 SD 3; 3 monthsa; 1 CR, 1 SD 2; 9 months; 2 SD None
Chung et al. [40] None 1; 5 monthsa; PR None None None
Yang et al. [41] None 3; NA; 1 PR, 1 SD, 1 PD 2; NA; 2 SD 1; NA; PD None
Ichihara et al. [42] None 2; 2.4 months; 2 SD None 1; 1.6 months; SD None
Pugh et al. [43] None 1; NA; PR 1; NA; PR None None
Kimura et al. [44] None 1; 5 months; PR None None None
Van Zandwijk et al. [45] None None 1; NA; PR None None
Jackman et al. [46] None 1; 14.8 monthsa; SD None None None
Pallis et al. [47] None 3; NA; 1 PR, 1 SD, 1 PD 1; NA; PD None None
Han et al. [48] None 1; 13.8 months; 1 SD 2; 3 months; 2 PR None None
Kosakaet al. [49] None 2; 24.5 months; 2 PR None None None
Choong et al. [50] None 1; 8 months; PR None None None
Oshita et al. [51] None 2; 13.2 months; 2 PR 1; 12 months; SD None None
Tokumo et al. [52] None 1; 2 months; PD None None None
Chou et al. [53] None None 2; 4.1 months; 1 PD, 1 PD None None
Shih et al. [54] None 2; NA; 2 PR 2; NA; 2 PR None None
Taron et al. [55] None 1; 9.4 months; PR None None None
Mitsudomi et al. [56] None 1, NA,1 PD None None None
Takano et al. [57] None 2; 12.6 months; 2 PR None None None
Pao et al. [58] None 1; 13 months; 1 PR None None None
Total, n 44 127 71 32 4
ORR, n (%) 31 (70.5%) 68 (53.5%) 34 (47.9%) 10 (31.2%) NA
mPFS, range (months) 2–17.5 1.9–24.5 1.1–12 1.6–10 6
  1. PFS progression-free survival, TKI tyrosine kinase inhibitor, mPFS median progression-free survival, PR partial response, NA not available, SD stable disease, PD progressive disease, CR complete response, SR serological response, ORR overall response rate
  2. amPFS not reached